Analyser av ADDvise Group

ADDvise Q3 2024: Comparables set to ease from Q4 2024e - Redeye

Redeye updates its estimates and valuation following ADDvise releasing its Q3 2024 report, which broadly missed our estimates.

Redeye • 25 okt 2024 10:46

ADDvise Q3 2024: Broad miss, comparables should ease next quarter - Redeye

Redeye provides its initial take on ADDvise’s Q3 2024 report, which came in broadly below our estimates.

Redeye • 24 okt 2024 11:57

Addvise Q2 2024: Road to recovery - Redeye

Redeye updates its estimates and valuation following ADDvise releasing its Q2 2024 report, which featured expectedly soft figures.

Redeye • 19 jul 2024 08:50

Addvise Q2 2024: Weak quarter, as expected - Redeye

Redeye provides its initial take on ADDvise’s Q2 2024 report, which came in broadly below our estimates.

Redeye • 18 jul 2024 08:59

ADDvise Q1 2024: Organic growth set to start improving in H2 2024e - Redeye

Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which featured weaker Healthcare sales and margin...

Redeye • 22 apr 2024 07:13

ADDvise Q1 2024: Soft Q1 figures due to continued mean reversion of pharmaceutical sales - Redeye

Redeye provides its initial take on ADDvise’s Q1 2024 report, which came in broadly below our estimates.

Redeye • 18 apr 2024 09:25

Addvise Group: In i lugnare fas - Mangold

ADDvise avslutade 2023 starkt. Bolaget uppvisade en hög tillväxt på 44,3 procent för helåret till 1373 miljoner kronor inkluderat fyra gjord...

Mangold • 26 feb 2024 08:24

ADDvise Q4 2023: Tough comparables depressed organic growth - Redeye

Redeye updates its estimates and valuation following ADDvise releasing its Q4 2023 report, which featured lower-than-expected sales and soli...

Redeye • 23 feb 2024 07:23

ADDvise Q4 2023: Lower-than-expected sales, solid margins - Redeye

Redeye provides its initial take on ADDvise’s Q4 2023 report, which came in moderately below our estimates.

Redeye • 22 feb 2024 09:14

ADDvise: Finetuning our estimates following recent M&A activity - Redeye

Redeye adjusts its estimates following ADDvise’s recent announcement of the acquisitions of Axelerist Inc.

Redeye • 02 jan 2024 14:07

Addvise: Ett styrkebesked - Mangold Insight Analys

Addvise, som förvärvar bolag inom hälso- och sjukvård, bjöd på ett starkt tredje kvartal.

Mangold • 30 okt 2023 13:09

ADDvise Q3 2023: The profitable growth story continues - Redeye

Redeye updates its estimates and valuation following ADDvise releasing its Q3 2023 report.

Redeye • 30 okt 2023 07:09

ADDvise Q3 2023: Lab sales above expectations and solid margins - Redeye

Redeye provides its initial take on ADDvise’s Q3 2023 report, which came in broadly above our estimates.

Redeye • 26 okt 2023 10:02

ADDvise: Lönsam tillväxt - Mangold

ADDvise, som förvärvar bolag inom hälso- och sjukvård bjöd på kraftigt förbättrad lönsamhet och fortsatt hög tillväxt under det andra kvarta...

Mangold • 21 jul 2023 14:23

ADDvise: Exceptional Quarter in Lab - Redeye

Redeye retains its positive view of ADDvise following a strong Q2 report in line with the preliminary results.

Redeye • 21 jul 2023 08:19

ADDvise Q2 2023: Strong Q2 in Line with Preliminary Figures - Redeye

Redeye retains its positive view on ADDvise following a Q2 report with numbers aligning with the preliminary figures.

Redeye • 20 jul 2023 08:34

ADDvise: Strong Preliminary Q2 Figures - Redeye

Redeye sees strong preliminary results for ADDvise’s Q2.

Redeye • 13 jul 2023 09:25

ADDvise: Raised Financial Targets, Brazilian Acquisition, and Refinancing - Redeye

Redeye increases its forecasts and Base Case in ADDvise somewhat following raised financial targets, the acquisition of Kolplast, and the re...

Redeye • 25 maj 2023 12:07

Addvise Group: Kommentar - Mangold

Mangold ser positivt på att ADDvise uppdaterat sina långsiktiga finansiella mål.

Mangold • 25 maj 2023 10:26

Addvise Group: Flygande start på året - Mangold

ADDvise, som förvärvar bolag inom hälso- och sjukvård, har fått en flygande start på 2023.

Mangold • 09 maj 2023 13:12

ADDvise: Strong Momentum Continues - Redeye

Redeye raises its Base Case, forecasts, and Redeye Rating for ADDvise following a streak of solid reports.

Redeye • 21 apr 2023 08:44

ADDvise Q1 2023: Strong Start to 2023 - Redeye

Redeye will likely increase its forecasts and Base Case following a solid Q1 report from ADDvise.

Redeye • 20 apr 2023 08:24

Addvise Group: Nischförvärvare i högform - Mangold

ADDvise, som förvärvar bolag inom hälso- och sjukvård, bjöd på rekordsiffror i sin bokslutskommuniké för 2022.

Mangold • 27 feb 2023 08:29

ADDvise: Solid Organic and Inorganic Momentum - Redeye

Redeye raises its Base Case and forecasts for ADDvise following a strong Q4 and the recent letters of intent to acquire.

Redeye • 24 feb 2023 08:14

ADDvise Q4 2022: Strong Numbers in Line with Preliminary Figures - Redeye

Redeye will likely raise its Base Case and forecasts following a strong Q4, in line with the preliminary figures.

Redeye • 23 feb 2023 09:42

ADDvise: Excellent Prel. Q4 Numbers - Redeye

Redeye reinforces its positive view of ADDvise following strong preliminary Q4 figures.

Redeye • 31 jan 2023 09:03

ADDvise: Solid Q3 and Outlook - Redeye

Redeye strengthens its positive view of ADDvise following a solid Q3 report, thanks to strong margins in the Healthcare segment.

Redeye • 07 nov 2022 07:18

Addvise Group: Står stark i orostider - Mangold

Addvise, en nischförvärvare av medicintekniska bolag, har via förvärv och hög organisk tillväxt ökat sin nettoomsättning med 103 procent und...

Mangold • 03 nov 2022 13:07

ADDvise Q3 2022: Strong Numbers - Redeye

Redeye strengthens its positive view of ADDvise following a Q3 report beating our forecasts on sales and EBITDA.

Redeye • 28 okt 2022 11:06

ADDvise: Quality Acquisition in the Netherlands - Redeye

Redeye strengthens its positive view on ADDvise following the large-high-quality acquisition of CliniChain.

Redeye • 09 sep 2022 12:10

Addvise: Förvärv ökar vinst - Mangold

Addvise, en nischförvärvare av medicintekniska bolag, har visat upp ett starkt andra kvartal.

Mangold • 25 jul 2022 09:43

ADDvise: Strong Contribution from M&A - Redeye

Redeye retains its positive view on ADDvise following a solid Q2 report, with a strong contribution from recently acquired businesses and ro...

Redeye • 25 jul 2022 08:22

ADDvise Q2: Solid Quarter, Slightly Above Forecasts - Redeye

Redeye retains its positive view on ADDvise following a Q2 report showing slightly better adjusted EBITDA than expected.

Redeye • 22 jul 2022 09:39

Addvise Group: Förvärvare siktar högt - Mangold

Addvise, en nischförvärvare av medicintekniska bolag, har inlett 2022 med hög förvärvad tillväxt och förbättrad lönsamhet.

Mangold • 04 maj 2022 10:20

ADDvise: Exciting 2022 Ahead - Redeye

Redeye raises its Base Case and forecasts slightly for ADDvise following a solid Q1 report.

Redeye • 26 apr 2022 10:08

ADDvise Q1’22: Initial Take - Redeye

Redeye will likely retain its positive view on ADDvise following the Q1 report.

Redeye • 22 apr 2022 09:11

ADDvise: M&A Fueled Growth Ahead - Redeye

Redeye retains its Base Case and long-term forecasts following a mixed Q4 report with strong sales and soft margins.

Redeye • 14 mar 2022 09:47

Addvise Group: Når högt satta mål - Mangold

Addvise, en nischförvärvare av medicintekniska bolag, har ökat sin tillväxt kraftigt under 2021.

Mangold • 28 feb 2022 13:31

ADDvise Q4’21 Review: Strong Sales, Somewhat Soft Margins - Redeye

Redeye’s preliminary revisions suggest reduced short-term margin assumptions while leaving our long-term forecasts unchanged, following a mi...

Redeye • 24 feb 2022 16:28

ADDvise Q4’21: Initial Take - Redeye

Redeye sees a mixed Q4 with strong sales but with rather soft margins.

Redeye • 24 feb 2022 11:28

Addvise Group: Hög tillväxt präglade kvartalet - Mangold

Addvise Group som växer genom förvärv inom hälso- och sjukvård, främst i Nordamerika, visade upp en hög tillväxttakt och en förbättrad brutt...

Mangold • 29 okt 2021 09:54

Addvise Group: Serieförvärvare växlar upp - Mangold

Mangold Insight uppdaterar Addvise med upprepad rekommendation Köp och höjd riktkurs till 10,00 kronor.

Mangold • 18 okt 2021 09:40

Addvise Group: Attracting Institutions - Redeye

Redeye raises its Base Case for ADDvise following a successful direct share issue and additional acquisitions.

Redeye • 14 sep 2021 11:30

Addvise Lab Solutions: Nya förvärv ger lyft - Mangold

Addvise har varit aktiva med förvärv under 2021 som väntas få stor påverkan på framtida resultatutveckling.

Mangold • 10 aug 2021 14:22

Addvise Lab Solutions: Expanding in the US - Redeye

Redeye takes a positive stance to ADDvise’s acquisition of Medisuite.

Redeye • 02 aug 2021 12:52

Addvise Lab Solutions: Q2’2021 Review: Improved Sales Mix Paying Off - Redeye

Redeye raises its forecast and Base case following a solid Q2 report beating our forecasts.

Redeye • 26 jul 2021 09:57

Addvise Lab Solutions: Q2’21, 9% EBIT Beat - Redeye

Redeye will likely increase its Base case and forecasts following a Q2 report, beating our EBIT forecasts by 9%.

Redeye • 23 jul 2021 12:38